FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

businesswire

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors – NEWSnet – News… as it used to be

More Press Releases

June 17, 2026

Google Cloud’s Model Garden at Platform 37: An Exclusive Customer Hub for AI Innovation and Collaboration

June 17, 2026

Herdyne Mercier Releases Mommy, What’s That Feeling? to Help Children Name and Heal from Big Emotions

June 17, 2026

Pepper Energy Partners Launches Iron Horse to Cut Data Storage Costs, Risk, and Inefficiency

June 17, 2026

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

Google Cloud’s Model Garden at Platform 37: An Exclusive Customer Hub for AI Innovation and Collaboration

Herdyne Mercier Releases Mommy, What’s That Feeling? to Help Children Name and Heal from Big Emotions

Pepper Energy Partners Launches Iron Horse to Cut Data Storage Costs, Risk, and Inefficiency

University of East-West Medicine Celebrates Inaugural Professional Doctorate Graduation Ceremony